Result Analysis of Total Hip Replacement in Sickle Cell Disease
Not Applicable
- Conditions
- Health Condition 1: M878- Other osteonecrosisHealth Condition 2: M878- Other osteonecrosis
- Registration Number
- CTRI/2024/05/067673
- Lead Sponsor
- Datta Meghe Institute of Higher Education and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All Sickle Cell Disease patients eligible to undergo Total Hip Arthroplasty
Exclusion Criteria
1. Patients undergoing Revision Total Hip Replacement
2. Patients with congenital anomalies of hip
3. Patients with a neurological deficit of the lower limb
4. Patients with ipsilateral knee/ankle/foot/Spine pathologies
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The study through the perioperative clinical outcome analysis, Functional outcome analysis in terms of VAS Score, Modified Harris Hip Score and Radiological outcome analysis through pre-operative M.R.I. and X-ray in the pre-operative and postoperative period in Sickle cell disease patients following Total Hip Arthroplasty.Timepoint: Pre-operative period, post-operatively within 2 weeks and follow up visits at 6-8 weeks, 12-14 weeks
- Secondary Outcome Measures
Name Time Method To outline the perioperative complications, problems, and difficulties in sickle cell disease patients undergoing total hip arthroplasty. Further, it offers a comparative outcome analysis of sickle cell disease patients and non-sickle cell disease patients undergoing Total hip arthroplasty.Timepoint: Pre-operative period, post-operatively within 2 weeks and follow up visits at 6-8 weeks, 12-14 weeks